MATERIAL DOWNLOADS
Welcome – J. M. Llibre
Long-acting ARV formulations knocking on the door – Courtney V. Fletcher
2DR Debate: The “Pro” argument – Chloe Orkin
2DR Debate: In support of three drug regimens – Laura Waters
Top DDI in clinical practice: Still relevant? – Catia Marzolini
New drugs for unmet needs. A clinician’s view – Jürgen Rockstroh
Industry Round Table: ViiV – R&D Strategy. Where are we heading? – Jan van Lunzen
Industry Round Table: Gilead – HIV Pipeline – Devi SenGupta
Industry Round Table: MSD – HIV Research Update – Fernando A. Bognar
Industry Round Table: Janssen – ¿Where are we headed? – Eugenia Vispo
Industry Round Table: Thera Technologies – Vision for the Future – Brandon Cash
How to reduce HIV incidence in Europe – Teymur Noori
Jump Start ART: Is it still relevant to E.U.? – Jean-Jacques Parienti
What we have achieved in Africa so far? So close yet so far away – Francois Venter
PrEP and STIs – STIs and PrEP – Pep Coll
NASH: The next liver epidemic in HIV? – James Maurice
Clinical Cases Discussion: Fertile woman with pregnancy potential – Franco Maggiolo
Clinical Cases Discussion: Drug resistance testing in naive patients – Carlo F. Perno
Clinical Cases Discussion: Young MSM with perianal a ulcer – Adrià Curran
Clinical Cases Discussion: Aging – Ignacio Bernardino